Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes in Patients with Recurrent Tonsillitis

2008 ◽  
Vol 12 (4) ◽  
pp. 517-521 ◽  
Author(s):  
Mohamad Bitar ◽  
Roy Khalaf ◽  
Wael Shamseddeen ◽  
Nady El Hajj ◽  
Georges Ibrahim ◽  
...  
Keyword(s):  
Killer Cell ◽  
Recurrent Tonsillitis ◽  
Kir Genotypes

scholarly journals Characterisation of B killer cell immunoglobulin-like receptor genes and telomeric and centromeric motifs in hematopoietic stem cell transplantation donors in Vojvodina, Serbia

Genetika ◽  
2017 ◽  
Vol 49 (1) ◽  
pp. 345-354
Author(s):  
Dusica Ademovic-Sazdanic ◽  
Svetlana Vojvodic ◽  
S. Popovic ◽  
N. Konstantinidis
Keyword(s):  
Relapse Prevention ◽  
Hematological Malignancies ◽  
Killer Cell ◽  
Simple Algorithm ◽  
Hematopoietic Stem ◽  
Graft Versus Host ◽  
Kir Genes ◽  
Graft Versus Leukemia ◽  
Kir Gene ◽  
Kir Genotypes

The outcome of HSCT is strongly in?uenced by the genetic similarity or identity in the HLA genes that affects the incidence of graft-versus-host disease (GvHD). Successful allogeneic HSCT, however, depends also on T-cell mediated graft-versus-leukemia (GvL) effect, in which donor-derived T cells and natural killer (NK) cells kill these malignant cells in the patient, therefore playing a crucial role in relapse prevention. The aim of this study was to make the predictive analysis of the structure and distribution of B KIR alleles and centromeric and telomeric KIR genotypes in HSCT donors in Vojvodina with regard to their contribution to protection from relapse. A total of 124 first-degree relatives of patients with hematological malignancies were examined for the presence or absence of 15 KIR genes by using of PCR-SSO technique with Luminex xMap technology. The percentage of individuals carrying each KIR gene, centromeric and telomeric KIR haplotypes and genotypes was determined by direct counting. Sixty two percent of the HSCT donors in Vojvodina carry A KIR haplotype, while nearly 38% carry B KIR haplotype. The distribution of B KIR genes showed that among 124 studied HSCT donors, 31(25%) do not carry none of the KIR genes belonging to B group, 71.77% of donors have two or more B KIR genes, 61.29% of them carry KIR 2DL2 and 2DS2 or more B KIR genes. The analysis of centromeric and telomeric KIR genotypes, showed that Cen-A1/Tel-A1 genotype had a highest frequency of 51.47% and Cen-B2/Tel-B1 the lowest frequency of 1.30%. The usage of donor KIR B gene content and centromeric and telomeric KIR gene structure could be used in development of a simple algorithm to identify donors who will provide the most protection against the relapse in related HSC transplants.

Characterization of Killer cell immunoglobulin-like receptor (KIR) genotypes and haplotypes in ChineseHanpopulation

2013 ◽  
Vol 82 (5) ◽  
pp. 327-337 ◽  
Author(s):  
X. Bao ◽  
M. Wang ◽  
H. Zhou ◽  
X. Wu ◽  
L. Yang ◽  
...  
Keyword(s):  
Killer Cell ◽  
Kir Genotypes

scholarly journals Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes

2021 ◽  
Vol 9 (4) ◽  
pp. e001705
Author(s):  
Barbara Manzanares-Martin ◽  
Arancha Cebrián Aranda ◽  
Laura del Puerto-Nevado ◽  
Rafael González ◽  
Sonia Solanes ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Group Performance ◽  
Killer Cell ◽  
Eastern Cooperative Oncology Group ◽  
Immunomodulatory Activity ◽  
Egfr Expression ◽  
Selection Of Patients ◽  
Kir Genotypes ◽  
Selection Of

AimCetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR (killer cell immunoglobulin-like receptor) genotyping can provide a significant added value in the clinical outcome of patients with KRAS mutant mCRC based on cetuximab treatment.MethodsWe included 69 patients with histologically confirmed mCRC and KRAS mutation, positive EGFR expression, and Eastern Cooperative Oncology Group performance status ≤2. Based on KIR gene content, haplotype (A or B) was defined and genotypes (AA or Bx) were grouped for each patient.ResultsWe demonstrated with new evidence the immunomodulatory activity of cetuximab in patients with KRAS mutant mCRC. Patients with homozygous genotypes (AA or BB) showed shorter 12-month progression-free survival (PFS12) and poorer overall survival (OS) than those with heterozygotes (AB). Moreover, multivariate analysis confirmed stratification of patients based on genotype was an independent marker of PFS12 (HR 2.16) and the centromeric and telomeric distribution of KIRs was an independent predictor of both PFS12 (HR 2.26) and OS (HR 1.93) in patients with mCRC with KRAS mutation treated with cetuximab.ConclusionsSelection of patients with mCRC based on their KIR genotypes opens a therapeutic opportunity for patients with KRAS mutation, and it should be tested in clinical trials in comparison with other alternatives with scarce benefit.Trial registration numberNCT01450319, EudraCT 2010-023580-18.

Natural Killer Cell Immunoglobulin-like Receptors (KIR) Genotypes in two Arab Populations: Will KIR become a genetic landmark between nations?

2007 ◽  
Vol 35 (2) ◽  
pp. 225-229 ◽  
Author(s):  
Roni Rayes ◽  
Ali Bazarbachi ◽  
Georges Khazen ◽  
Amira Sabbagh ◽  
Ghazi Zaatari ◽  
...  
Keyword(s):  
Natural Killer Cell ◽  
Natural Killer ◽  
Killer Cell ◽  
Kir Genotypes

Distribution of Killer Cell Immunoglobulin–like Receptor (KIR) Genotypes in Patients with Familial Mediterranean Fever

2009 ◽  
Vol 13 (1) ◽  
pp. 91-95 ◽  
Author(s):  
Rami A.R. Mahfouz ◽  
Amira S. Sabbagh ◽  
Wael Shamseddine ◽  
Ali Bazarbachi ◽  
Georges Ibrahim ◽  
...  
Keyword(s):  
Familial Mediterranean Fever ◽  
Killer Cell ◽  
Mediterranean Fever ◽  
Kir Genotypes

Clinical Implications of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes on Autologous Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia Patients.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1537-1537
Author(s):  
Heeje Kim ◽  
Young Choi ◽  
Tai-Hyang Lee ◽  
Dong-Hoon Hahn ◽  
Hoei-Sung Gang ◽  
...  
Keyword(s):  
Nk Cells ◽  
Killer Cell ◽  
Myelogenous Leukemia ◽  
Term Survival ◽  
Kir Genes ◽  
Acute Myelogenous ◽  
Kir Genotypes ◽  
Autologous Hsct

Abstract Natural killer (NK) cell alloreactivity after allogeneic hematopoietic stem cell transplantation (HSCT) in various settings is introduced by the regulatory role of killer cell immunoglobulin-like receptors (KIR). However, no influence of NK cells on relapse or survival after autologous HSCT for patients with acute myelogenous leukemia (AML) has been demonstrated. Since it is still debated whether autologous NK cells are involved in the eradication of leukemia cells, we evaluated the role of NK cells as a susceptibility factor for long-term survival. All 67 enrolled patients who received autologous HSCT were typed for the presence or absence of 19 different KIR genes and pseudogenes using a polymerase chain reaction-based sequence-specific primer method with the Pel-Freez kit, according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA). The median follow-up was 21 months (range 2–55). All patients were in first complete remission (CR), as assessed immediately before the elective transplantation. The median age of the enrolled patients was 42 years (range 16–68). There were 33 females and 34 males. All patients received our modified TAM conditioning, which consisted of fractionated total body irradiation (12 Gy, five fractions in 3 days) from day −8 to −6, followed by intermediate-dose cytarabine (Ara-C; 1.5 g/m2 over 3 h every 12 h for six doses) from day −5 to −3, and melphalan (100 mg/m2 over 30 min) on day −2 only. The peripheral blood stem cells were collected after administering granulocyte colony-stimulating factor, following consolidation chemotherapy. The patients had 7–13 KIR genes, which is similar to the range in the normal population. The median infused cell dose was 4.2 × 106/kg (range 1.7–6.3) CD34+ cells. Fifty patients were alive (75%). Of the 67 patients, 43 were in continuous CR (64%) and 14 died in relapse (21%), while 3 (4%) died due to non-relapse causes. The Kaplan-Meier estimated 4-year disease-free survival (DFS) rate was 55% (95% CI 47–62%). We evaluated whether the presence or absence of any single or combination of inhibitory or activating KIR genes in the patients affected DFS and eventfree survival (EFS). The presence of an activating KIR 2DS1 gene was critical for the DFS and EFS, as shown in a previous study of allogeneic HSCT (Kim et al., Transplantation 2007). Additionally, the presence of two activating genes in the combinations 2DS3-2DS4*003 or 2DS4*003-2DS5 tended to be associated with DFS (P=0.0866). Since our findings are based on a single disease entity, i.e., adult AML, they suggest that the presence of activating KIR genes may, at least in some ways, be critical for autologous NK immunomodulation to influence the anti-leukemic effects, especially considering the impact of activating KIR genotypes on long-term survival.

scholarly journals Diversity of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome

PLoS ONE ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. e99426 ◽  
Author(s):  
Jose Ramón Vidal-Castiñeira ◽  
Antonio López-Vázquez ◽  
Jesús Martínez-Borra ◽  
Pablo Martínez-Camblor ◽  
Jesús Prieto ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Killer Cell ◽  
Hcv Treatment ◽  
Kir Genotypes

Natural Killer Cell Immunoglobulin-like Receptor (KIR) genotypes in Follicular Lymphoma patients: Results of a pilot study

Gene ◽  
2013 ◽  
Vol 525 (1) ◽  
pp. 136-140 ◽  
Author(s):  
Roy Khalaf ◽  
Rouba Hoteit ◽  
Soha Yazbek ◽  
Nady El Hajj ◽  
Zaher Otrock ◽  
...  
Keyword(s):  
Pilot Study ◽  
Natural Killer Cell ◽  
Follicular Lymphoma ◽  
Natural Killer ◽  
Killer Cell ◽  
Kir Genotypes
Sign in / Sign up

Export Citation Format

Share Document